Bempedoic acid

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Bempedoic acid
Accession Number
DB11936
Type
Small Molecule
Groups
Investigational
Description

Bempedoic acid has been used in trials studying the treatment of Hypertension, Dyslipidemia, Hyperlipidemia, Type 2 Diabetes, and Hypercholesterolemia, among others.

Structure
Thumb
Synonyms
Not Available
External IDs
ESP-55016 / ETC-1002 / ETC1002
Categories
UNII
1EJ6Z6Q368
CAS number
738606-46-7
Weight
Average: 344.492
Monoisotopic: 344.256274259
Chemical Formula
C19H36O5
InChI Key
HYHMLYSLQUKXKP-UHFFFAOYSA-N
InChI
InChI=1S/C19H36O5/c1-18(2,16(21)22)13-9-5-7-11-15(20)12-8-6-10-14-19(3,4)17(23)24/h15,20H,5-14H2,1-4H3,(H,21,22)(H,23,24)
IUPAC Name
8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid
SMILES
CC(C)(CCCCCC(O)CCCCCC(C)(C)C(O)=O)C(O)=O

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
2,4-thiazolidinedioneThe risk or severity of hypoglycemia can be increased when 2,4-thiazolidinedione is combined with Bempedoic acid.
5-(2-methylpiperazine-1-sulfonyl)isoquinolineThe therapeutic efficacy of Bempedoic acid can be increased when used in combination with 5-(2-methylpiperazine-1-sulfonyl)isoquinoline.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypoglycemic activities of Bempedoic acid.
AcarboseThe risk or severity of hypoglycemia can be increased when Acarbose is combined with Bempedoic acid.
AcebutololThe therapeutic efficacy of Bempedoic acid can be increased when used in combination with Acebutolol.
AcetazolamideThe therapeutic efficacy of Bempedoic acid can be increased when used in combination with Acetazolamide.
AcetohexamideThe risk or severity of hypoglycemia can be increased when Acetohexamide is combined with Bempedoic acid.
Acetyl sulfisoxazoleThe therapeutic efficacy of Bempedoic acid can be increased when used in combination with Acetyl sulfisoxazole.
Acetylsalicylic acidThe risk or severity of hypoglycemia can be increased when Acetylsalicylic acid is combined with Bempedoic acid.
AgmatineThe risk or severity of hypoglycemia can be increased when Agmatine is combined with Bempedoic acid.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
10472693
PubChem Substance
347828263
ChemSpider
8648104
ChEMBL
CHEMBL3545313
Wikipedia
Bempedoic_acid

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedDiagnosticHyperlipidemias1
1CompletedTreatmentSafety Evaluation of Escalating Doses1
2CompletedTreatmentCholesterolemia / Diabetes / Type 2 Diabetes Mellitus1
2CompletedTreatmentDyslipidemia1
2CompletedTreatmentHigh Blood Pressure (Hypertension) / High Cholesterol1
2CompletedTreatmentHigh Cholesterol6
2CompletedTreatmentHyperlipidemias1
2CompletedTreatmentHyperlipidemias / Type 2 Diabetes Mellitus1
3Active Not RecruitingTreatmentAtherosclerotic Cardiovascular Diseases / High Cholesterol1
3CompletedTreatmentAtherosclerosis / High Cholesterol / Statin Adverse Reaction1
3CompletedTreatmentAtherosclerotic Cardiovascular Diseases / High Cholesterol2
3CompletedTreatmentAtherosclerotic Cardiovascular Diseases / High Cholesterol / Statin Adverse Reaction1
3CompletedTreatmentHyperlipidemias1
3RecruitingTreatmentCardiovascular Heart Disease / Statin Adverse Reaction1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0211 mg/mLALOGPS
logP3.65ALOGPS
logP5.3ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)4.44ChemAxon
pKa (Strongest Basic)-1.3ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count14ChemAxon
Refractivity93.97 m3·mol-1ChemAxon
Polarizability41.08 Å3ChemAxon
Number of Rings0ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as long-chain fatty acids. These are fatty acids with an aliphatic tail that contains between 13 and 21 carbon atoms.
Kingdom
Organic compounds
Super Class
Lipids and lipid-like molecules
Class
Fatty Acyls
Sub Class
Fatty acids and conjugates
Direct Parent
Long-chain fatty acids
Alternative Parents
Methyl-branched fatty acids / Hydroxy fatty acids / Dicarboxylic acids and derivatives / Secondary alcohols / Carboxylic acids / Organic oxides / Hydrocarbon derivatives / Carbonyl compounds
Substituents
Long-chain fatty acid / Methyl-branched fatty acid / Hydroxy fatty acid / Branched fatty acid / Dicarboxylic acid or derivatives / Secondary alcohol / Carboxylic acid / Carboxylic acid derivative / Organic oxygen compound / Organic oxide
Molecular Framework
Aliphatic acyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 15:02 / Updated on December 02, 2019 09:14